Crohn’s Disease (CD) Treatment Market Future Opportunities, Revenue Growth, Pricing And Profitability 2023 to 2033

 The global Crohn's Disease (CD) Treatment Market is anticipated to be valued at US$ 11.68 billion by the end of 2023. According to Future Market Insights, the market will grow at a 4.3% CAGR from 2023 to 2033, reaching a market value of around US$ 17.8 billion by the end of 2033.

The incidence of ulcerative colitis and Crohn's disease is on the rise, which is a significant factor driving the growth of the global market for treatments for the condition. A few other factors that should be considered when creating a Crohn's disease therapy to support market expansion are the increasing prevalence of the disease and the growing awareness of it worldwide.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16809

The availability of drugs to manage the symptoms of inflammatory bowel disease, such as adalimumab, infliximab, certolizumab, and golimumab, also contributes to the market's expansion. Also, according to an article from NCBI 2020, ulcerative colitis is thought to affect 9 to 20 people per 100,000 people year, with 156 to 291 instances occurring in the regions of North America and Europe. Therefore, increasing ulcerative colitis instances result in increased demand for Crohn's disease treatments, which in turn propels the expansion of the Crohn's disease medications market.

The development of new therapeutic approaches for various Inflammatory Bowel Diseases (IBD) like ulcerative colitis and crohn's disease through key players' collaborations is expected to increase the adoption of inorganic strategies within the global market for treating crohn's disease over the course of the forecast period. For example, the Crohn's & Colitis Foundation and Inotrem, a biotech company in advanced clinical stages that specializes in immune checkpoint inhibitors for chronic as well as acute inflammatory syndromes, declared a scientific and technological collaboration agreement in April 2022 to support the development of a novel therapeutic strategy for Crohn's disease. Such developments are anticipated to open up new opportunities in the global market for Crohn’s disease treatment during the forecast period.

Key Takeaways from the Market Study

  • The Crohn's disease treatment market expanded historically between 2018 and 2022 at a CAGR of 3.2%.
  • More than $11.2 billion is presently spent on treating Crohn's disease globally.
  • Immunomodulators are predicted to lead the medication type sector in 2023 with a 53% revenue share.
  • The hospital pharmacy sector by distribution channel will maintain the second-largest segment during the anticipated period, with a global market share of 27.3% in 2023.
  • From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 4.9%.
  • From 2023 to 2033, the Asia Pacific Crohn's Disease Treatment Market is anticipated to expand at a stable CAGR of 3.6%.

“The increasing prevalence of ulcerative colitis and Crohn’s disease along with innovative pipeline of biological therapies and medications are expected to accelerate the growth during the forecast period,” comments a Future Market Insights analyst.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/crohns-disease-treatment-market

Competitive Landscape

Some of the top players in the global intraocular lymphoma disease market are:

  • Abbvie Inc.
  • Celgene Corporation
  • Genetech
  • Johnson & Johnson
  • Pfizer
  • Prometheus Laboratories Inc. (Nestle)
  • Salix Pharmaceuticals Inc.
  • Takeda's Pharmaceutical Ltd
  • Janssen Pharmaceuticals
  • Biogen
  • AstraZeneca

Some of the recent developments in this domain are:

  • In 2022, AbbVie said that SKYRIZI® (risankizumab-rzaa) has received FDA approval to be used in the management of moderately to highly active Crohn's disease. The interleukin-23 (IL-23) inhibitor SKYRIZI binds to the p19 component of IL-23 to specifically inhibit it. A variety of chronic immune-mediated disorders, including Crohn's disease, are suspected to be related to IL-23, a cytokine implicated in inflammatory processes.
  • Tiziana Life Sciences, a biotechnology firm that enables breakthrough immunotherapies through innovative modes of monoclonal antibody administration, announced the start of a Phase 1b clinical study in 2022 to test foralumab enteric-coated capsules orally delivered in people who have mild to moderate Crohn's Disease (CD). A unique method of inducing an anti-inflammatory immune reaction by site-targeted immunomodulation in the intestine is oral administration of foralumab.

Key Segments Covered in the Crohn's Disease Treatment Market Report

By Drug Type:

  • Antibiotics
  • Amino Salicylates
  • Corticosteroids
  • Immunomodulators
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Comments

Post a Comment

Popular posts from this blog

Orthopedic Trauma Devices Market is projected to reach a valuation of US$ 21.2 Bn by 2033 | FMI

Image
  The net worth of the Orthopaedic Trauma Devices Market is expected to increase from US$ 10.7 billion in 2023 to more than US$ 21.2 billion by 2033. From 2023 to 2033, the orthopaedic trauma device market is expected to grow at a 7.1% CAGR . To learn more about this report @ https://www.futuremarketinsights.com/reports/orthopedic-trauma-devices-market With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Orthopedic Trauma Devices market. FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Orthopedic Trauma Devices market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision. Over the past decade, healthcar
Read more

Insulin Pen Market is forecasted to surpass US$ 46.9 Bn by 2031

Image
Diabetes is becoming more common as poor lifestyle choices continue to be prominent around the world. Insulin pens are a widely used method of treating diabetic individuals. Given this, Future Market Insights predicts that insulin pen sales will reach US$ 30,407 million in 2021. Insulin pens are used by diabetes patients to avoid problems including cardiovascular diseases that may arise from this lifestyle-based ailment. To overcome problems related to conventional methods of insulin administration, insulin pens make the process easier and faster. Get More Information on this Report @ https://www.futuremarketinsights.com/reports/insulin-pens-market According to the WHO, approximately 1.2 million deaths were caused due to diabetes in 2019 globally. To reduce the number of deaths or sufferings due to diabetes, the development of innovative techniques and products for the treatment and maintenance of diabetes is essential. Type 2 diabetes cases are common, but it can be prevented or de
Read more

Molecular Biology Enzymes, Kits & Reagents Market Size, Share, Growth, Forecast through 2032

Image
  According to a recent Future Market Insights report, the global Molecular Biology Enzymes, Kits & Reagents Market will grow dramatically between 2022 and 2032. By 2032, global sales of molecular biology enzymes, kits, and reagents are expected to total approximately US$ 48,476.41 million. Technological Advancements Leading to Enhanced Efficiency & Greater Precision of Molecular Biology Enzymes, Kits & Reagents The manufacturers of molecular biology enzymes, kits, and reagents have contributed significantly to technical breakthroughs by focusing on creating cutting-edge goods in an effort to diversify their product offerings. The cutting-edge items support the study procedures by providing features like increased precision and efficiency. One of the best instances of this is Thermo Fisher Scientific, Inc.’s SMART Digest Kit, which was created specifically for biopharmaceutical and proteomic applications. This kit reduces the time required for sample preparation while
Read more